Tech Transfer eNews Blog

Spinout from Harvard and Boston Children’s develops novel therapeutics targeting pain and itch neurons


By Jesse Schwartz
Published: April 24th, 2019

A spinout from Harvard University and Boston Children’s Hospital is developing novel pharmaceuticals to provide effective, sustained relief for serious medical conditions such as cough, itch, pain and inflammation.

Nocion Pharmaceuticals aims to provide highly selective, locally confined drugs targeting sensory neurons that have responded to noxious stimuli, all without inhibiting the neurons that mediate movement or touch.

“Our novel approach to selectively inhibiting neurons, resulting from a fundamental understanding of how the body responds to insult, will result in differentiated therapeutics addressing a host of unmet medical needs,” says Richard Batycky, CEO of Nocion. “A confluence of world-class founders and venture partners positions Nocion on the right path to have a meaningful impact on patients’ lives.”

The company was built on the work of two of its scientific founders, Bruce Bean and Clifford Woolf, who are based at Harvard and Boston Children’s Hospital. With support from Harvard’s Blavatnik Biomedical Accelerator and Boston Children’s Technology Development Fund, Bean and Woolf developed their research on sensory neurons into a targeted approach to treating a range of health afflictions.

Bruce Levy, a researcher at Brigham and Women’s Hospital in Boston, teamed up with Bean and Clifford to test their research in in vivo models of lung inflammation and cough. Levy also serves as scientific co-founder of Nocion.

“The unique molecular approach to selectively silence activated nocioceptors, developed by my co-founders, addresses many of the limitations of traditional therapeutics in the class that prevent broader utilization, and may prove to offer better effects for patients,” says Levy. “We’re hopeful that these innovations may be applicable in many tissues and clinical conditions in the skin, lungs, GI tract, mouth, eye and beyond to help alleviate patient suffering.”

The Harvard Office of Technology Development helped Nocion secure an exclusive license from the university and Boston Children’s, and the company has raised $27 million in Series A financing to support clinical trials.

Source: Nocion Therapeutics

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment